1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6211)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13088)
  2. Department of Medicine (13004)
  3. Center for Hematologic Malignancies (10395)
  4. GSK Faculty (4422)
  5. Adult Leukemia (3583)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (775)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (204)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (431)

More Publishers

Results (13088)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and functional studies reveal that TP73 isoforms levels are associated with prognosis and RA-resistance in acute promyelocytic leukemia
    Meeting Abstract

    Rojas, C. A. O.; Pereira-Martins, D. A.; Weinhäuser, I.; Almeida, L. Y.; Bianco, T. M.; Figueiredo-Pontes, L. L.; Koury, L. C. A.; Melo, R. A. M.; Bittencourt, R.; Pagnano, K. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II clinical trial of CPI-613 (devimistat) in patients with relapsed or refractory burkitt lymphoma/leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2and/or BCL6
    Meeting Abstract

    Noy, A.; Pardee, T. S.; Nikolaenko, L.; Steiner, R. E.; Abramson, J. S.; Dunleavy, K.; Luther, S.
    Blood (2019)

    Fulltext@MSK | Save
  • Dynamic easix scores closely predict non-relapse mortality after allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Nawas, M. T.; Sanchez-Escamilla, M.; Devlin, S. M.; Maloy, M. A.; Giralt, S. A.; Perales, M. A.; Scordo, M.
    Blood (2019)

    Fulltext@MSK | Save
  • Preliminary results from a phase II study of the combination of pevonedistat and azacitidine in the treatment of MDS and MDS/MPN after failure of DNA methyltransferase inhibition
    Meeting Abstract

    Moyo, T. K.; Watts, J. M.; Skikne, B. S.; Mendler, J. H.; Klimek, V. M.; Chen, S. C.; Fan, R.; Anderson, I. A.; Sochacki, A.; Strickland, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Igcaller: Reconstructing the rearranged immunoglobulin gene in lymphoid neoplasms from whole-genome sequencing data
    Meeting Abstract

    Nadeu, F.; Mas-de-les-Valls, R.; Royo, R.; Navarro, A.; Beà, S.; Lu, J.; Rivas-Delgado, A.; Villamor, N.; Martín, S.; Aymerich, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B-cell lymphoma
    Meeting Abstract

    Mondello, P.; Tarantelli, C.; Cascione, L.; Arribas, A.; Rinaldi, A.; Younes, A.; Bertoni, F.
    Blood (2019)

    Fulltext@MSK | Save
  • Combinatorial genetics uncovers novel targets for the treatment of Npm1/cohesin mutated AML
    Meeting Abstract

    Meyer, A. E.; Stelloh, C.; Fisher, J. B.; Pulakanti, K.; Vassiliou, G. S.; Viny, A. D.; Levine, R. L.; Rao, S.
    Blood (2019)

    Fulltext@MSK | Save